The coronavirus vaccine being developed by Pfizer and BioNTech has been found to be 90% effective in preventing people from getting the virus, it has been confirmed.
Phase 3 of Pfizer’s trial involved 43,538 participants. They received two doses of either the immunisation or a placebo, with 90% protected from the virus within 28 days of having their jabs.
Only 94 people who took part in the trial developed coronavirus and no serious safety concerns were reported, the pharmaceutical firm said on Monday.
“Today is a great day for science and humanity. The first set of results from our Phase 3Â COVID-19Â vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Pfizer chairman and chief executive Dr Albert Bourla.
“With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.
“While we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality,” he added.
Pfizer and BioNTech’s vaccine is one of many being developed around the world in the race to end the global pandemic.
The two companies say they can supply 50 million doses by the end of 2020 and 1.3 billion by the end of 2021.
PLEASE SUPPORT US FOR JUST £2 A MONTH
